Skip to main content
. 2016 Jun 24;11(6):e0158242. doi: 10.1371/journal.pone.0158242

Fig 2. Association of KIR genotype mismatching with chronic GVHD was confirmed using a multivariate competing risks regression model.

Fig 2

Effect of KIR genotype mismatching on aGVHD grade II-IV (left panel), cGVHD needing systemic therapy (middle panel) and relapse (right panel) was analyzed using multivariate competing risks regression model (Fine and Gray method) across discovery [A], validation [B] and combined [C] cohorts. Graft failure, relapse, second malignancy or death occurring before the onset of cGVHD was considered competing risks for cGVHD. Graft failure, second malignancy or non-relapse death occurring before the onset of relapse was considered competing risk for relapse. P values <0.05 were considered statistically significant. Favorable effect of KIR genotype matched donors on cGVHD (middle panel) was confirmed across discovery and validation cohorts in addition to all analyzed cases.